Literature DB >> 343914

Fanconi syndrome associated with cephalothin and gentamicin therapy.

J H Schwartz, P Schein.   

Abstract

A case is reported of Fanconi syndrome and nonliquric renal failure, following a brief course of cephalothin and gentamicin, in a patient with diffuse histiocytic lymphoma. These drugs, especially when used in combination, have been associated with nephrotoxicity manifested as acute tubular necrosis and altered proximal tubular function, but biochemical evidence for generalized proximal tubular dysfunction has not been accurately defined. Thus far, only two other antibiotics, degraded tetracycline and streptozotocin, have been implicated in producing an acquired Fanconi syndrome.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 343914     DOI: 10.1002/1097-0142(197802)41:2<769::aid-cncr2820410251>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases.

Authors:  Yong Lin; Fan Pan; Yingchao Wang; Ziqian Chen; Chun Lin; Lvfeng Yao; Xin Zhang; Rui Zhou; Chen Pan
Journal:  Oncol Lett       Date:  2016-11-17       Impact factor: 2.967

2.  [Toxic nephropathies (author's transl)].

Authors:  E Heidbreder; A Heidland
Journal:  Klin Wochenschr       Date:  1980-02-01

3.  Effect of cephapirin on tubular reabsorption of amino acids, uric acid and beta 2-microglobulin in man.

Authors:  A Arvidsson; G Alván; O Borgå; R Eklöf
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

Review 4.  Aminoglycosides--50 years on.

Authors:  E J Begg; M L Barclay
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

5.  Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.

Authors:  Jack E Heron; Mark Bloch; Vinay Vanguru; John Saunders; David M Gracey
Journal:  BMC Nephrol       Date:  2020-08-12       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.